Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation  by Au, Brandon K.C. et al.
Biol Blood Marrow Transplant 21 (2015) 848e854Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgReevaluation of the Pretransplant Assessment of Mortality
Score after Allogeneic Hematopoietic TransplantationBrandon K.C. Au 1, Ted A. Gooley 2, Philippe Armand 3, Min Fang 2, David K. Madtes 4,
Mohamed L. Sorror 4, Michael J. Boeckh 4, Christopher J. Gibson 5, Hans Joachim Deeg 4,
Rainer Storb 4, Frederick R. Appelbaum4, Jason W. Chien 2, Paul J. Martin 4,*
1Department of Medicine, University of Washington, Seattle, Washington
2Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
3Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts
4Division of Clinical Research, Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington
5Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MassachusettsArticle history:
Received 25 November 2014
Accepted 12 January 2015
Key Words:
Allogeneic hematopoietic cell
transplantation
Survival
Comorbidity
Risk assessmentFinancial disclosure: See Acknowl
* Correspondence and reprint re
inson Cancer Research Center, P.O.
WA 98109-1024.
E-mail address: pmartin@fhcrc
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
The Pretransplant Assessment of Mortality (PAM) score was developed in 2006 to predict risk of mortality
after allogeneic hematopoietic cell transplantation (HCT). Transplant practices have evolved during the past
decade, suggesting the need to reevaluate the performance of the PAM score. We used statistical modeling to
analyze and recalibrate mortality based on overall PAM scores, its components, and conditioning regimen in a
retrospective cohort of 1549 patients who had HCT from 2003 through 2009. PAM scores correlated with
mortality, but the effect size was smaller in the current study than in previous studies. PAM scores also
demonstrated a stronger association with mortality in patients who received myeloablative conditioning than
in those who received reduced-intensity conditioning. In contrast to the original study, carbon monoxide
diffusing capacity, serum alanine aminotransferase, and serum creatinine concentrations were no longer
signiﬁcantly associated with 2-year mortality, whereas patient and donor cytomegalovirus serology was
associated with mortality in the current cohort. Based on our ﬁndings, we developed and tested a revised
PAM score for clinicians to estimate survival after allogeneic HCT with myeloablative conditioning regimens
for patients with hematologic malignancy. Prognostic models such as the PAM score should be updated and
recalibrated periodically to accommodate changes in clinical practice.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT)
continues to be associated with high early mortality
compared with other treatments for hematologic malig-
nancies. Clinical tools to estimate this risk include the
Pretransplant Assessment for Mortality (PAM) score, which
uniquely integrates patient age, disease risk, selected
transplant variables and certain measures of comorbidity
to predict the risk of all-cause mortality at 2 years. Trans-
plant variables in the PAM score include donor relation-
ship, HLA matching, and type of conditioning regimen,
whereas measures of comorbidity include forcededgments on page 853
quests: Paul J. Martin, MD, Fred Hutch-
Box 19024, 1100 Fairview Ave. N., Seattle,
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15.01.011
ty for Blood and Marrow Transplantation.expiratory volume in 1 second (FEV1), carbon monoxide
diffusing capacity (DLCO), serum creatinine concentration,
and serum alanine aminotransferase (ALT) concentration
[1]. The 50-point scoring system demonstrated a strong
ability to predict 2-year mortality risk (Supplemental
Table 1). Subsequent attempts to validate the PAM score
in other studies have had mixed results [2-6].
Transplant practices have evolved during the past
decade, including the increased use of nonmyeloablative or
reduced-intensity conditioning (RIC) before trans-
plantation. These changes suggest the need to re-evaluate
the performance of HCT-related prognostic models such as
the PAM score. The goal of the current study therefore was
to determine the extent to which the PAM score and its
components continue to predict mortality after HCT and to
assess the performance of the PAMmodel based on the type
of conditioning regimen. The latter was not well deﬁned in
the original study because of the limited numbers of pa-
tients treated with RIC regimens.
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Patient Cohorts
The current cohort for this study included ﬁrst-time allogeneic HCT
recipients at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer
Research Center from January 1, 2003 through December 31, 2009. All pa-
tients were followed until death or the last day of contact as of December 31,
2011. We used the validation cohort from the previous study [1] (1990
through 2002) for comparison with the current cohort (Table 1). The Insti-
tutional Review Board determined that the use of deidentiﬁed patient in-
formation was exempt from review. To create an external validation cohort,
additional data were obtained from the Dana Farber Cancer Institute (DFCI)
and Brigham andWomen’s Hospital for HCT recipients from January 1, 2005
through June 30, 2009, with approval of the DFCI Institutional Review Board.
Clinical Variables
Donor type was determined according to HLA compatibility and
patientedonor relation. Conditioning regimens were classiﬁed as myeloa-
blative or reduced intensity (nonmyeloablative). Myeloablative regimens
varied but typically contained high-dose cyclophosphamide with busulfan
or 12.0 to 13.2 Gy total body irradiation (TBI), busulfan or treosulfan with
ﬂudarabine, or radiolabeled CD45-speciﬁc monoclonal antibody with ﬂu-
darabine and 2 Gy TBI [7]. Conditioning regimens containing radiolabeled
antibody were categorized as equivalent to >12 Gy TBI. Reduced-intensity
regimens included 2 to 3 Gy TBI with or without ﬂudarabine [8]. Pulmo-
nary function testing was performed according to American Thoracic Society
guidelines [9-11]. DLCO was adjusted for hemoglobin concentration ac-
cording to the Dinakara equation [12]. FEV1 and DLCO were expressed as a
percentage of predicted values [13,14] and were capped at 100%, because
higher values are not known to have physiologic signiﬁcance with respect to
HCT.
Statistical Analysis
Cox regression was used to assess the association of PAM score and
individual PAM components with 2-year all-cause mortality, with follow-up
censored at 2 years. PAM score and its continuous individual components
were modeled as continuous variables, both linear and nonlinear, where the
nonlinear modeling was done using a cubic spline with knots at the 5th,
25th, 50th, 75th, and 95th percentiles [15]. A cubic spline provides a ﬂexible
way to model continuous associations with outcome and requires minimal
assumptions regarding a particular functional form. PAM components were
also modeled categorically with the same cut-points used in the original
report. PAM scores were categorized into various groups, and survival curves
for patients in each group were plotted as Kaplan-Meier estimates.
The associations of PAM and its components with mortality in the cur-
rent cohort were compared with the associations in the validation cohort
from the original PAM study. We used the validation cohort because inclu-
sion of patients from the original development cohort would overestimateTable 1
Baseline Clinical Characteristics of the Previous Validation and Current PAM
Cohorts
Factor Previous Cohort* Current Cohort*
Median patient age, yr (range) 41.8 (15.0-72.5) 50.7 (15.1-78.9)
Disease risk,y n (%)
Low 382 (29) 237 (15)
Intermediate 358 (27) 885 (57)
High 574 (44) 427 (28)
Donor type, n (%)
Related/matched 670 (51) 584 (38)
Related/mismatched 125 (10) 79 (5)
Unrelated 519 (39) 886 (57)
Conditioning, n (%)
Reduced intensity 72 (5) 609 (39)
Myeloablative, no TBI 469 (36) 547 (35)
Myeloablative, TBI  12 Gy 326 (25) 253 (16)
Myeloablative, TBI > 12 Gy 497 (34) 140 (9)
Median creatinine, mg/dL (range) .8 (.3-5.7) .9 (.3-9.7)
Median ALT, U/mL (range) 27 (0-908) 23 (4-349)
Median FEV1, % of
predicted (range)
93.1 (26.4-100) 92.2 (32.0-100)
Median DLCO, % of
predicted (range)
99.2 (9.7-100) 80.0 (31.2-100)
* Date range October 1, 1990 through December 31, 2002 for the previous
cohort compared with January 1, 2003 through December 31, 2009 for the
current cohort.
y Categorized according to reference 1.the performance of PAM and the association of PAM and its components
with outcome. The performance of PAM was reassessed using a c-statistic
(see Supplemental Data). The Akaike information criteria were also calcu-
lated to assess model ﬁt, where smaller values indicate a better ﬁt.
The interactions of PAM score with conditioning intensity and cohort
were assessed by ﬁtting the appropriate term in a Cox regression model,
with PAMmodeled as a continuous linear variable. A revised PAM score was
developed from patients in the current cohort who received myeloablative
conditioning for hematologic malignancy. The performance and ﬁt of the
revised PAM score was assessed through bootstrapping (see Supplemental
Data). The external validation cohort was also used to assess the perfor-
mance of the revised PAM score. All statistical analyses were performed
using SAS (Version 9.3, SAS Institute, Inc., Cary, NC).
RESULTS
Cohort Characteristics
We identiﬁed 1665 patients who received a ﬁrst alloge-
neic HCT between January 1, 2003 and December 31, 2009.
Data for all 8 PAM components were available for 1549 pa-
tients: 940 treated with myeloablative conditioning and 609
treated with RIC. Table 1 summarizes baseline clinical char-
acteristics of the current cohort and the previous validation
cohort. The overall mean PAM score was 23.1 (median 23,
range 8 to 43) in the current cohort, and the distributions of
PAM scores were similar for patients who received myeloa-
blative conditioning (mean 23.3, median 24, range 11 to 43)
or RIC (mean 22.9, median 22, range 8 to 41).
Association of PAM with Outcome and Performance of
PAM in the Current Cohort versus Previous Validation
Cohort
In the current cohort, increasing PAM score was associ-
ated with a higher risk of death. With PAM score modeled as
a continuous linear variable, the risk of death from any cause
increased by 8% with each 1-point increase in PAM score
(hazard ratio [HR], 1.08; 95% conﬁdence interval [CI], 1.07 to
1.10; P< .0001). This result compares with a relative increase
of 12% in the previous PAM validation cohort (HR, 1.12; 95%
CI, 1.11 to 11.14; P < .0001). A statistically signiﬁcant inter-
action between score and cohort was observed (P < .0001),
indicating the magnitude of the association of score with
outcome differed between the 2 cohorts. Modeling the PAM
score as a cubic spline visually showed the strength of the
association was weaker in the current cohort than in the
previous cohort (Figure 1). The c-statistic for PAM was .62
(95% CI, .60 to .64) for the current cohort, compared with .68
(95% CI, .67 to 0.70) in the previous validation cohort.
Figure 2 shows the association of PAM with survival to 2
years for the current cohort and the previous validation
cohort. Patients with the highest PAM scores in the current
cohort demonstrated improved survival compared with
those in the previous validation cohort. Although increasing
PAM score is still clearly associated with decreased survival,
the strength of the association in the current cohort is
weaker than in the previous validation cohort, and the per-
formance of PAM has diminished.
Association of PAM with Outcome and Performance of
PAM in the Current Cohort, Myeloablative versus RIC
The proportion of patients who received RIC was higher
in the current cohort (39%) than in the original PAM valida-
tion cohort (5%). We hypothesized that the strength of as-
sociation between PAM and risk of mortality would be
greater among patients who received myeloablative condi-
tioning as compared with RIC, thereby partially explaining
the weaker association between PAM score and outcome in
the current study as compared with the original report. For
Figure 1. Association of PAM score and the hazard of 2-year mortality when
PAM is modeled as a cubic spline. Association is examined separately for pa-
tients in the previous validation cohort and for patients in the current cohort.
HRs are indicated by thicker lines; pointwise 95% CIs are indicated by thinner
lines.
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current cohort, the risk of death by 2 years post-transplant
increased by 10% for each 1-point increase in PAM score
(HR, 1.10; 95% CI, 1.08 to 1.12; P < .0001). For patients who
received RIC, the risk of death by 2 years increased by 6% for
each 1-point increase in PAM score (HR, 1.06; 95% CI, 1.03 to
1.08; P < .0001). These data suggest the magnitude of asso-
ciation of the PAM score with mortality is larger in the
myeloablative group than in the RIC group, with a test of
statistical interaction yielding P ¼ .002. Kaplan-Meier sur-
vival curves by conditioning regimen for speciﬁed PAM
groupings are available in Supplemental Figure 1. The
concordance of PAM with mortality was higher in the mye-
loablative group than in the RIC group (c ¼ .64 [95% CI, .62 to
0.67] and c ¼ .57 [95% CI, .54 to .60], respectively).
Association of PAM with Outcome and Performance of
PAM with Myeloablative Conditioning, Current Cohort
versus Previous Validation Cohort
Differences in performance of the PAM score and reduc-
tion in the magnitude of association with outcome were alsoFigure 2. Two-year survival for the current (A) and previous validation (B) cohorts, g
scores were grouped as <17, 17-23, 24-30, and >30, with the upper interval of the ﬁrst
50%, and 75%, respectively, based on data from the original PAM development cohort.
PAM 24-30; category 4 (green): PAM > 30. Absolute probabilities of survival are 79%
previous validation cohort, respectively.seen when the comparison of the current cohort with the
previous validation cohort was restricted to patients who
received myeloablative conditioning. We observed a 13%
increase in 2-year mortality for each 1-point increase in PAM
score (HR, 1.13; 95% CI, 1.11 to 1.14; P < .0001) in the previous
validation cohort and 10% (HR, 1.10; 95% CI, 1.08 to 1.12; P <
.0001) in the current cohort. A test of interaction between
the PAM score and cohort yields P ¼ .02, and Supplemental
Figure 2 shows the association when the PAM score was
modeled as a cubic spline. These results indicate that the
magnitude of the association of PAM with mortality differed
in the 2 cohorts. Among patients who receivedmyeloablative
conditioning, the c-statistic was .69 (95% CI, .67 to 0.71) for
the previous validation cohort and .64 (95% CI, .62 to .67) for
the current cohort.Individual PAM Variables Compared Between the
Previous Validation and Current Cohorts among Patients
Who Received Myeloablative Conditioning
Given the decrease in magnitude of the association of
PAM with outcome, we examined the association of each
PAM component with outcome after HCT with myeloablative
conditioning in both the current cohort and previous vali-
dation cohort. The adjusted association of each of the
continuous factors with the risk of 2-year mortality is sum-
marized in Figure 3, where the continuous factors not in
question were modeled as linear functions for adjustment
purposes. In the previous validation cohort, the associations
between mortality and all continuous variables were statis-
tically signiﬁcant. In the current cohort, the associations
between 2-year mortality and creatinine (linear P ¼ .76,
nonlinear versus linear P ¼ .38, cubic spline P ¼ .40), ALT
(linear P ¼ .78, nonlinear versus linear P ¼ .32, cubic spline
P¼ .47), and DLCO (linear P ¼ .20, nonlinear versus linear P ¼
.51, cubic spline P ¼ .42) were not statistically signiﬁcant.
The increased mortality risk associated with age appears
to occur later in the current cohort than in the previous
cohort. Results in the current cohort show a statistically
signiﬁcant positive association (linear P ¼ .02, nonlinear
versus linear P ¼ .03, cubic spline P ¼ .007), but the data
suggest the association is nonlinear. The association between
FEV1 and outcome was statistically signiﬁcant in the current
cohort (linear P ¼ .006, nonlinear versus linear P ¼ .77, cubic
spline P ¼ .009), similar to results in the previous validationrouped into 4 separate PAM categorizations based on the original study, where
3 windows chosen so the predicted probabilities of death by 2 years were 25%,
Category 1 (black): PAM < 17; category 2 (red): PAM 17-23; category 3 (blue):
, 63%, 47%, and 33% in the current cohort and 84%, 66%, 38%, and 17% in the
Figure 3. HRs for 2-year mortality with individual PAM variables modeled as cubic splines in the previous validation (black) and current (red) cohorts for patients
who received myeloablative conditioning. (A) patient age; (B) ALT; (C) creatinine; (D) DLCO; (E) FEV1. HRs are indicated by thicker lines; pointwise 95% CIs are
indicated by thinner lines.
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PAM components as originally categorized for both the cur-
rent cohort and previous validation cohort, where notably
both disease risk and type of donor were associated with
outcome in the current cohort.
Development and Testing of a Revised PAM Model
Data from 914 patients in the current cohort who were
diagnosed with a hematologic malignancy, received mye-
loablative conditioning, and had cytogenetic data available
were used to develop a revised PAMmodel, where all factors
considered for the original PAM score were re-examined [1].
Whereas the previous PAM model used an older disease risk
classiﬁcation, we reorganized overall risk groups according
to a more updated risk index developed by Armand et al.
[16]. In the original PAM model, unrelated donors were
considered as a single group regardless of HLA matching or
stem cell source. In the new model, we stratiﬁed unrelated
donors using HLA matching (HR 1.40, P¼ .007 for 10/10 HLA-
matched unrelated donors and HR 2.07, P < .0001 for 9/10
HLA-matched unrelated donors compared with HLA-
matched related donors) and separated unrelated cord
blood donors as a distinct group (HR 2.19, P ¼ .002). Patient
age, donor type, disease risk, FEV1, and patient and donorcytomegalovirus (CMV) serology (P ¼ .0005) were included
in the revised PAM, with FEV1 modeled as a continuous
linear variable. Even though the association with age
appeared to be nonlinear, a model with age dichotomized
provided a better ﬁt to the data as compared with the more
complex model with a nonlinear function of age. Table 2
summarizes the scores and associations for the categorical
and continuous factors for the revised PAM.
A separate cohort of 401 patients from DFCI was used to
validate the revised PAM score, using the same selection
criteria applied in themodel-building cohort. Except for CMV
(and age, where there were no patients older than 65), each
of the revised PAM components was associated with 2-year
mortality in the DFCI cohort (Supplemental Table 3).
Modeling PAM as a continuous linear variable, each increase
in PAM by 1 point was associated with an 8% increase in 2-
year mortality (HR, 1.08; 95% CI, 1.06 to 1.10; P < .0001).
The assumption of linearity was consistent with the data
when modeling PAM as a cubic spline (Supplemental
Figure 3). Figure 4 displays Kaplan-Meier survival curves
for the external validation cohort with PAM scores divided
into 5 groupings of roughly equal interval lengths.
The bias-corrected Akaike information criteria for the
revised PAM model was smaller compared with the original
Table 2
Factors Included in Revised PAM Model and Their Association with 2-Year Mortality
Variable HR (95% CI) P Score*
Patient age, yr
<65 Reference d 0
65 2.13 .0004 7.6
Donor type Global P < .0001
HLA-matched, related Reference d 0
Unrelated, 10/10y 1.40 (1.10-1.79) .007 3.4
Unrelated, 9/10y 2.07 (1.57-2.47) <.0001 7.3
Unrelated, cord blood 2.19 (1.35-3.57) .002 7.9
HLA-mismatched, related 2.00 (1.10-3.64) .02 6.9
Disease riskz Global P < .0001
Low Reference d 0
Intermediate 1.71 (1.07-2.75) .03 5.4
High 3.75 (2.30-6.12) <.0001 13.2
Very high 5.49 (3.19-9.44) <.0001 17.0
FEV1 1.20x (1.09-1.28) <.0001 0.181  (100  %FEV1)
Patient/donor CMV Global P ¼ .0003
/ Reference 0
/þ 1.71 (1.20-2.44) .003 5.4
þ/ 1.70 (1.31-2.21) <.0001 5.3
þ/þ 1.41 (1.07-1.86) .01 3.5
* The score for each group of the categorical components was obtained bymultiplying the appropriate regression coefﬁcient by 10. For the continuous variable
FEV1, the regression coefﬁcient was multiplied by 10 to yield .168. Moreover, to ensure that all PAM scores generated were greater than zero, FEV1 was
transformed to 100  %FEV1 so the score for this component is zero when FEV1 ¼ 100% and positive when FEV1 is less than 100%.
y HLA matching includes HLA-A, -B, -C, -DR, and -DQ alleles.
z Overall risk groups were determined according to the risk index developed by Armand et al. [16], which includes disease risk, stage risk, and cytogenetic data
for acute myeloid leukemia and myelodysplastic syndromes (MDS). The poor and very poor MDS cytogenetic risk categories deﬁned by Deeg et al. [27] were
grouped as high-risk disease, and all other categories were grouped as intermediate-risk disease.
x Represents the relative change in HR for each decrease in FEV1 by 10%.
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5042.3), and the bias-corrected c-statistic using the revised
PAM score was .65, which is comparable with the value of .64
for thepreviousPAMwhenapplied to thecurrent cohort. Thec-
statistic for the revised PAM in the external validation cohort
was .63 (95% CI, .60 to .66). These data suggest that the per-
formance of the revised PAM score is similar to the previous
PAMscore inﬁtting the data and inpredicting 2-yearmortality.
DISCUSSION
The PAM score was originally published in 2006 as a
simple and effective clinical scoring system and predictor of
mortality [1]. Our follow-up analysis of the PAM score showsFigure 4. Two-year survival for the external validation cohort (n ¼ 401) from
the Dana Farber Cancer Institute, grouped into 5 separate PAM categorizations
that were divided into intervals of similar length. The stratiﬁcation of group-
ings by equal interval lengths is supported by Supplemental Figure 3, because
the association appears relatively linear. Category 1 (black): PAM 0-9; category
2 (red): PAM 9-14; category 3 (blue): PAM 14-19; category 4 (green): PAM 19-
24; category 5 (pink): PAM 24-41.the performance of the original PAM score has diminished
over time, as has the strength of the association with 2-year
mortality. Similar changes are likely to occur with other
predictive models [17-20].
Several factors likely contributed to the decreased
discriminatory capacity of the PAM score and the loss of as-
sociations of ALT, creatinine, and DLCO with mortality. Data
have demonstrated improved outcomes after HCT over time
[21]. In comparing patients who had HCT from 1993 to 1997
and from 2003 to 2007, Gooley et al. [21] showed signiﬁcant
reductions in nonrelapse mortality, all-cause mortality, liver
dysfunction, acute kidney injury, and pulmonary complica-
tions through day 100. It is likely that changes in transplant
practice and supportive care and the ability to manage
comorbidities have all contributed to improved outcomes
after HCT. Abnormalities in ALT, creatinine, and DLCO in the
current study cohort of patients who received myeloablative
conditioning regimens were relatively mild and do not
extend to the range that can be allowed with RIC regimens.
Patients with ALT, creatinine, or DLCO abnormalities more
severe than observed in this study are very likely to experi-
ence higher risks of mortality after HCT with myeloablative
conditioning regimens.
In updating the PAM model, we used a recently reﬁned
disease risk classiﬁcation, stratiﬁed unrelated donors ac-
cording to HLAmatching, and analyzed cord blood recipients
as a separate group. The differences in HRs assigned to each
unrelated donor group now reﬂect a more accurately
weighted contribution to the revised PAM model. The asso-
ciation between CMV status and mortality in the current
cohort is consistent with a recently published large multi-
center European analysis [22]. The sample size of the vali-
dation cohort may have been too small to detect this
association, especially because the CMV effect is relatively
small. Of note, the HRs for the CMV effect in both the current
PAM study and the European study were within the 95% CI
around the HR in the validation cohort.
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RIC regimens than in those treated with myeloablative reg-
imens, as indicated by the c-statistic estimates and the sta-
tistical models (both cubic spline modeling and
categorization of PAM score). Comorbidities not included in
the PAM score are more likely to occur in patients treated
with RIC regimens than in those treated with myeloablative
regimens, and the omission of these comorbidities contrib-
utes to the relatively poor performance of the PAM score in
predicting outcomes after RIC HCT. As expected, older age
and comorbidities have lesser effects after RIC HCT as
compared with myeloablative regimens. Additionally, dif-
ferences in outcome according to disease risk groups used in
the original PAM report (and duplicated here) were smaller
in patients who received RIC as compared with myeloa-
blative conditioning. After RIC, the intermediate- and high-
risk groups were 1.34 and 1.61, respectively, times more
likely to die by 2 years compared with patients in the low-
risk group [23]. After myeloablative conditioning, these
HRs were 1.97 and 4.61, respectively.
The PAM score and the HCT-speciﬁc comorbidity index
(HCT-CI) [24] represent different tools for prognostication
after HCT. The PAM score was developed as a simple global
prognostic tool that incorporates patient age, selected
comorbidities, disease risk, and donor type to predict overall
survival at 2 years. In contrast, the HCT-CI is a comorbidity
index designed speciﬁcally to capture the burden of multiple
organ dysfunctions (n ¼ 17 comorbidities) before allogeneic
HCT to predict the risk of nonrelapse mortality. The HCT-CI
was recently modiﬁed to incorporate patient age as an
additional risk factor for nonrelapse mortality [25]. Even
though this HCT-CI/age score does not consider disease risk
or donor type, its performance in predicting survival is
similar to its performance in predicting nonrelapse mortality
[25]. The PAM and HCT-CI scores should complement each
other, because each has components the other does not.
Previous results have shown that consideration of disease
severity led to a statistically signiﬁcantly improved model
when added to a model containing HCT-CI [26]. Similarly, we
expect that consideration of certain components of HCT-CI
would lead to a statistically signiﬁcantly improved model
when added to PAM. Both HCT-CI and PAM scores therefore
provide useful information.
Our study has several limitations. Although the data
clearly showed a change in association between PAM and
mortality, it is impossible within the scope of this study to
prove the underlying reason for these changes. The cubic
spline graphs clearly demonstrate the relationship between
PAM variables and mortality is complex and dynamic as
opposed to simple and static, highlighting the potential
limitations of categorical modeling. Results from these
models could be used to select the most appropriate cutoffs
for categorical analyses or, ideally, to develop more sophis-
ticated noncategorical algorithms for estimating survival
probabilities. The revised PAM score might not apply to pa-
tients with diseases other than hematologic malignancies
and does not apply to patients treated with RIC regimens.
In summary, the association between PAM and mortality
has changed over time. Its performance and the strength of
association with outcome have diminished, and the risk
factors for mortality have also changed. PAM provides better
prediction for patients treated with myeloablative condi-
tioning regimens than for those treated with RIC regimens.
All components in the PAM score can be easily ascertained by
referring physicians, although the FEV1 is seldom measuredbefore patients arrive at the transplant center, unless they
have pulmonary symptoms. If this information is available,
then the updated correlation between PAM score and sur-
vival after HCT (available at www.pamscore.org) may assist
clinicians in counseling patients during the initial discussion
about the beneﬁts and risks of HCT. The PAM score could also
be used in balancing cohorts of patients involved in clinical
trials. Our results indicate that prognostic tools should be re-
evaluated and reﬁned periodically, especially when clinical
practices or patient characteristics change over time.ACKNOWLEDGMENTS
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